NEW YORK, Sept. 26 - Dresdner Kleinwort Wasserstein has begun covering a handful of “special niche” genomic and proteomic companies, the financial company said on Wednesday.

The coverage, which will be led by analyst Charles C. Duncan, will include Celgene, CuraGen, Exelixis, Human Genome Sciences, Millennium Pharmaceuticals, Myriad Genetics, Tularik, and Vertex Pharmaceuticals. These all were rated a “Buy,” the company said in a statement. Two more companies, Celera Genomics and Sangamo BioSciences, were rated an “Add.”

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.